alpha-synuclein and ropinirole

alpha-synuclein has been researched along with ropinirole* in 1 studies

Reviews

1 review(s) available for alpha-synuclein and ropinirole

ArticleYear
Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease.
    Neuropharmacology, 2020, 10-15, Volume: 177

    Parkinson's disease (PD) is a progressive neurodegenerative disease due to the degeneration of dopaminergic neurons in substantia nigra pars compacta of the mid brain. The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model of PD. α-synuclein accumulation in the brain of flies (PD flies) leads to the damage of dopaminergic neurons, dopamine depletion, impaired muscular coordination, memory decline and increase in oxidative stress. Ingestion of the RPAgNC by Drosophila significantly prevented the neuronal degeneration compared to only ropinirole. The results confirm that the RPAgNC exerts more neuro-protective effect compared to dopamine agonist i.e. ropinirole as such drug in experimental PD flies. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

    Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Drosophila melanogaster; Humans; Indoles; Male; Nanocomposites; Neurodegenerative Diseases; Parkinsonian Disorders; Silver

2020